| Autor: |
Kasuki, Leandro, Lamback, Elisa, Antunes, Ximene, Gadelha, Mônica R. |
| Předmět: |
|
| Zdroj: |
Expert Review of Endocrinology & Metabolism; 2024, Vol. 19 Issue 1, p71-80, 10p |
| Abstrakt: |
Medical treatment of acromegaly is based in a 'trial and error' approach. First-generation somatostatin receptor ligands (fg-SRL) are prescribed as first-line medical therapy to the vast majority of patients, despite lack of disease control in approximately 60% of patients. However, other drugs used in acromegaly treatment are available (cabergoline, pasireotide and pegvisomant). In this article, we review and discuss the biomarkers of response to medical treatment in acromegaly. Biomarkers for fg-SRL that can already be applied in clinical practice are: gender, age, pretreatment GH and IGF-I levels, cytokeratin granulation pattern, and the expression of somatostatin receptor type 2. Using biomarkers of response could guide treatment towards precision medicine with greater efficacy and lower costs. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
